Chicago Partners Investment Group’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.1M | Buy |
22,731
+2,502
| +12% | +$107K | 0.02% | 612 |
|
|
2026
Q1 | $792K | Sell |
20,229
-1,843
| -8% | -$87.3K | 0.02% | 647 |
|
|
2025
Q4 | $1.37M | Buy |
22,072
+1,686
| +8% | +$86.2K | 0.03% | 378 |
|
|
2025
Q3 | $1.06M | Buy |
20,386
+2,194
| +12% | +$128K | 0.03% | 417 |
|
|
2025
Q2 | $1.27M | Buy |
18,192
+35
| +0.2% | +$2.38K | 0.04% | 345 |
|
|
2025
Q1 | $1.23M | Sell |
18,157
-631
| -3% | -$52.1K | 0.04% | 326 |
|
|
2024
Q4 | $1.61M | Buy |
18,788
+1,283
| +7% | +$139K | 0.05% | 258 |
|
|
2024
Q3 | $2.03M | Buy |
17,505
+28
| +0.2% | +$3.73K | 0.07% | 214 |
|
|
2024
Q2 | $2.26M | Buy |
17,477
+83
| +0.5% | +$11K | 0.09% | 205 |
|
|
2024
Q1 | $2.24M | Sell |
17,394
-487
| -3% | -$58K | 0.1% | 195 |
|
|
2023
Q4 | $1.88M | Sell |
17,881
-2,801
| -14% | -$277K | 0.09% | 207 |
|
|
2023
Q3 | $2.01M | Sell |
20,682
-1,044
| -5% | -$92K | 0.11% | 181 |
|
|
2023
Q2 | $1.72M | Buy |
21,726
+146
| +0.7% | +$11.9K | 0.09% | 212 |
|
|
2023
Q1 | $1.84M | Buy |
21,580
+1,480
| +7% | +$105K | 0.11% | 186 |
|
|
2022
Q4 | $1.4M | Sell |
20,100
-2,844
| -12% | -$167K | 0.09% | 215 |
|
|
2022
Q3 | $1.32M | Hold |
22,944
| – | – | 0.09% | 192 |
|
|
2022
Q2 | $1.33M | Sell |
22,944
-1,366
| -6% | -$75.8K | 0.1% | 189 |
|
|
2022
Q1 | $1.26M | Buy |
24,310
+5,694
| +31% | +$292K | 0.1% | 179 |
|
|
2021
Q4 | $913K | Hold |
18,616
| – | – | 0.06% | 236 |
|
|
2021
Q3 | $1.06M | Hold |
18,616
| – | – | 0.07% | 216 |
|
|
2021
Q2 | $831K | Sell |
18,616
-2,400
| -11% | -$93K | 0.06% | 242 |
|
|
2021
Q1 | $779K | Buy |
21,016
+2,000
| +11% | +$71.2K | 0.06% | 236 |
|
|
2020
Q4 | $692K | Sell |
19,016
-402
| -2% | -$13.9K | 0.07% | 223 |
|
|
2020
Q3 | $634K | Buy |
19,418
+6,300
| +48% | +$210K | 0.08% | 197 |
|
|
2020
Q2 | $442K | Buy |
13,118
+216
| +2% | +$6.89K | 0.06% | 232 |
|
|
2020
Q1 | $407K | Hold |
12,902
| – | – | 0.06% | 215 |
|
|
2019
Q4 | $396K | Hold |
12,902
| – | – | 0.05% | 240 |
|
|
2019
Q3 | $350K | Buy |
+12,902
| New | +$326K | 0.05% | 234 |
|
|
2018
Q4 | – | Sell |
-6,288
| Closed | -$134K | – | 713 |
|
|
2018
Q3 | $134K | Buy |
6,288
+26
| +0.4% | +$634 | 0.02% | 356 |
|
|
2018
Q2 | $144K | Buy |
6,262
+5,536
| +763% | +$132K | 0.02% | 329 |
|
|
2018
Q1 | $18K | Sell |
726
-158
| -18% | -$4.15K | ﹤0.01% | 663 |
|
|
2017
Q4 | $24K | Sell |
884
-16
| -2% | -$407 | ﹤0.01% | 580 |
|
|
2017
Q3 | $22K | Sell |
900
-740
| -45% | -$16.7K | ﹤0.01% | 611 |
|
|
2017
Q2 | $32K | Buy |
+1,640
| New | +$33.1K | 0.01% | 455 |
|
Other funds holding NVO
F
Chicago Partners Investment Group's NVO Position: Q2 2026 in Review
Chicago Partners Investment Group increased its Novo Nordisk (NVO) stake by 12% in Q2 2026, buying an estimated $107K and bringing the position to 22,731 shares worth $1.1M. The position accounts for 0.02% of the portfolio, ranked #612.
Chicago Partners Investment Group first reported a position in NVO in Q2 2017 and has held it in 34 quarters since. The position peaked at $2.26M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.
- Chicago Partners Investment Group held 22,731 shares of Novo Nordisk worth $1.1M as of Q2 2026.
- Chicago Partners Investment Group bought 2,502 Novo Nordisk shares in Q2 2026, an estimated $107K.
- Novo Nordisk made up 0.02% of Chicago Partners Investment Group's portfolio in Q2 2026, its #612 holding.
- Chicago Partners Investment Group first reported a position in Novo Nordisk in Q2 2017 and has held it in 34 quarters since.
- Chicago Partners Investment Group's Novo Nordisk position peaked at $2.26M in Q2 2024.
- 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.
Based on Chicago Partners Investment Group's 13F filing for Q2 2026, filed 30 Jul 2026.